A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors
Status:
Completed
Trial end date:
2020-11-19
Target enrollment:
Participant gender:
Summary
This is a phase IIIb, single arm, open-label, multi-center study to evaluate the safety and
tolerability of emicizumab in participants with congenital hemophilia A who have documented
inhibitors against Factor VIII (FVIII) at enrollment. Approximately 200 participants, aged 12
or older, will be enrolled in this study and are expected to be enrolled at approximately 85
sites globally. Participants will receive an initial weekly dose of prophylactic emicizumab
subcutaneously for 4 weeks, followed by a weekly maintenance dose subcutaneously for the
remainder of the 2-year treatment period.